Sunshine Biopharma INC DEF 14A proxy statements
Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.
NASDAQ
Sunshine Biopharma Inc. announced its 2025 Annual Meeting of Shareholders to vote on director elections, auditor ratification, and an equity incentive plan amendment.
NASDAQ
Sunshine Biopharma Inc. will hold its 2025 Annual Meeting to elect directors, ratify auditors, and vote on a significant increase in its equity incentive plan shares.
NASDAQ
Sunshine Biopharma Inc. announces its 2024 Annual Meeting of Shareholders to be held virtually on December 10, 2024, to elect directors and ratify the appointment of its independent auditor.
NASDAQ
Sunshine Biopharma is implementing a reverse stock split of up to 1-for-60 to regain compliance with Nasdaq's minimum bid price requirement.
NASDAQ
Sunshine Biopharma intends to effectuate a reverse stock split of up to 1-for-200 to regain compliance with Nasdaq listing requirements.
NASDAQ
Sunshine Biopharma obtained stockholder approval for certain warrant provisions related to a recent $10 million public offering to ensure compliance with Nasdaq listing rules.